Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
Read transcripts of webcasts and audiocasts
Read transcripts of webcasts and audiocasts
Disclaimer: This is a machine-generated transcript and may contain inaccuracies.
Good morning, everybody, and welcome to the first quarter 2026 results call and webcast. My name is Katie Jackson. I'm responsible for investor relations and sustainability here at Terveystalo Group. As usual, we'll go through the results with our CEO Ville Iho and our CFO Juuso Pajunen. And after the presentation, you'll have time for your questions. Without further ado, Ville, over to you.
Thank you, Katie, and good morning. Let's dive into it. So first quarter. During the first quarter, the market was even more negative than we expected going into the year. That was then clearly reflected in our revenue line, which came clearly down. And the adjustment measures we undertook, especially in our operations, were aimed at adapting to a lower demand environment. There was a drop through to our Adjusted EBIT, which was at €34 million. Quality across the operations and services. High as per standard. Even improving, which is of course a positive sign of a very professional and robust organisation delivering in any circumstances. If one then dives a little bit deeper into what's happening in the Healthcare Services market, it is a market that is exceptionally negative this time around. We have not seen this type of a dip since the start of Covid. And basically all of the segments, regardless of what data you look, all of the segments and services are roughly -5 to 10% down. The positive thing and silver lining with this one is that we are seeing a market bottoming out. So, according to our judgment. And that's reflected also in our plans and actions. The bottom has been passed. And now the market shall start to grow gradually but steadily from a low level. In our own operations, as we have reported earlier, we have been suffering from a lower number of connected employees. And that one as well. We see bottoming out. So, going forward. And now. Now the number has been stable throughout the quarter. And now looking at the sales funnel activities, looking at the renewals, looking at new opportunities, looking at win rates. We can, with confidence, say that we start turning this one into positive going into H2. Of course, the progress will not be rapid because this is B2B business, and turning agreements around will take a while. But anyway, our market and own portfolio has bottomed out, and now we can start developing from this new base. A little bit different reasons and different levers into that one. Different reasons and different levers were pertinent to it. But the bottom line was that the market conditions were very tough during Q1 2026. Despite that, of course, the absolute result level and profitability we achieved was high, and we can be pleased with our own performance. But now the eyes need to be fixed on growth going forward. Market will not give even though it starts gradually improving. It will not give anything for free. We still focus and concentrate on our own agenda, which is very much geared to boost growth in all of our segments, with efforts in Healthcare Services concentrating on the occupational health care turnaround program and transforming it to deliver higher value and foster growth for our customers. We are renewing our offering for insurance customers and companies and intensifying cooperation with the insurance companies. We are focusing on segments that are growing in our traditional integrated care. One prime example is seniors, where we have captured big markets in Kela 65, and it continues developing positively for us. And of course, on top of this one, we are seeking drastic improvements in efficiency with our digital agenda in traditional operations, in digital techniques, and also in prevention, in portfolio business. Of course, a positive move from our side is dental growth. Actually, dental has been a positive highlight during Q1 2026. It has. The market conditions have been fairly, fairly good, and the team has done very good work in improving the business. And with the deal, the platform will be ever, ever stronger. And an integration of that platform, Juuso will comment on the phasing and timing of that one. Later in the presentation, we are actively engaging with healthcare counties. It is evident that they are very low with their purchases still, but at one point that market will activate, and we want to capture our fair share and even more from that one. In Sweden, market conditions have been tough. Now, the efficiency is there, and we are operationally improving. Now, the focus is on commercial actions and driving the revenue line with high operating leverage and improving profitability through that. Cycle is cycle. And it's clearly very, very negative at present. But we need to look beyond this cycle. As I said, the market will start gradually improving. But every time a strong cycle goes through an industry, some things change permanently. And that, coupled with the accelerating speed of technology development, will mean that we need to be even speedier than the transformation of this industry. And we need to invest in all three modalities, particularly in healthcare services delivery and integrated care. We are investing in Ella. We are making the life of our professionals easier, simpler, more efficient. And we are giving more time for professionals with patients in digital healthcare retail. We are improving the customer engagement call centers. We are investing in digital techniques and AI-assisted appointments. And efficiency potential in this modality is huge. We are also starting to invest in preventive care at scale. So, digital engagement through digital and based on data, proactive engagement with our customers, being relevant when they need, actively guiding them through their lifelong health journey, and looking for new growth in this emerging new market. We have the dry powder. We have the agenda and we have the speed in executing in all of these three buckets. Two landmark milestones in this development during Q1: Terveystalo launched its new novel occupational healthcare digital platform for its first clients. This one is next level compared to current platforms in the marketplace. It's developed jointly with our joint venture, Medhelp. And it's now live. And it's used by the first paying customers. Early feedback from the market is very positive. We continue scaling this one rapidly throughout the year. And as I said, this is next level. This is future. And this will give far more value for our customers and better insights into their own personnel than before. We have introduced AI assisted appointments and we are scaling that one. We have introduced AI-assisted appointments and we are scaling that one. Also, during the year, the efficiency potential in this modality is huge. We are also scaling volumes so that, with intelligent steering engines, we can steer more volumes in the digital modalities. At the same time, we are improving traditional physician-led integrated care. The prime tool is Ella, which we have launched. It's the user interface for our physicians. And already now we have gained some 30% efficiency improvement with the new platform. and at the same time, we have been able to to give more time to, to, to physicians and patients as we continue to scale, scale this one up during the year, within next 12 months, this is going to bypass any present platforms in the marketplace and will be a clear and powerful asset for, for their versatile. So market has been negative. It has bottomed out. We have an agenda for growth. We continue investing. We continue accelerating our technology journey. Thank you, Ville.
Thank you Ville. So good morning all. I'm Juuso Pajunen, CFO of Terveystalo Group. Let's go to the topic numbers. Everything else is negative, with the exception of the Net Promoter Score (NPS) for appointments, which is improving and still stands at 88. We see negative figures across everything else, excluding the Net Promoter Score (NPS) for appointments, which is improving and is still 88. But outside of that one, each and every number is negative and the market has been weaker than anticipated. But let's go through then number by number. What we are talking about. But before we go to that one, it is good to note that if we look at the absolute numbers, these are still quite robust figures. Our Q1 is materially above our average Q1 when it comes to absolute profitability. If we look in absolute EBITDA terms, this is the third best quarter ever in absolute EBITDA or EBIT, the way you want to look at it. So in absolute terms, we are fairly strong, but relative terms. We are absolutely disappointed and obviously will work to move forward. If we then look at the group, we know that our main challenge is the headwinds in revenue. We also know that the megatrends are there, and in mid to long term they will support the growth. But as stated, the market sentiment at the moment is exceptionally weak. If we then look on different segments, we will go a bit further into details. But in the Healthcare Services, the big thing is occupational health. It is the public sector. Sweden. We are now evening out. Then if we look at the group level and think about positives, our efficiency is strong no matter how you view it. In an exceptionally weak market, we have been able to adjust our operations towards the lower demand, and we will continue to do so. So all in all, with the efficiency, we will get forward. If we then look at the EPS impacting adjustment items, we have €7 million of these. It is slightly more than I would like to see in there. But if we double-click those, we have €1 million related to the divestment of child welfare, which was a strategic move, and we have now closed that deal. At the end of January, we have a €1 million related to re-evaluation of the values in the real estate assets. We are investing in those assets. And this is something that, when you re-evaluate, will take place. And then finally €1 million related to restructuring. It's good to know that these are structural restructuring items that impact us in the future, not restructurings driven by demand. And then finally, we have €4 million in strategic projects, which we have communicated earlier and for which we have provided annual guidance. This is slightly front heavy now, facing a bit more in Q1 than I was anticipating. So all in all, then we end up in the reported EBIT of €26.6 million. If we then go deeper into the Healthcare Services, margins are on a historically good level. So if we take any period of time and if we look to Q1 historically, the actual EBITDA and EBIT margins are solid, but obviously they are materially declining. So we come into the discussion of relative weakness and absolute weakness. And if we look further into the source, this is coming from demand. The visit growth is -9.6%. And then everything else is basically flat. The visit growth. We will double click that one on the next slide. But basically low morbidity impacts us through two different parts. We have fewer appointments and a weaker case mix, as diagnostic activity is lower than in a situation with higher upper respiratory disease activity. And then obviously, the occupational healthcare has been contributing to that one. At the same time, as mentioned, we are continuously adjusting for the lower demand. And we have also, during April, announced statutory negotiations due to the demand situation. And however, of these ones, once again, in absolute terms, we are in a good place, and we will continue to invest in, for example, digital transformation, as we explained. Then looking at the patient visits, we have now been going through the same factors in a couple of different quarters. We have the seasonality. We do know that we have some 43,000 fewer upper respiratory diseases than the previous year. This is part of normal variation and changes annually. This is the lowest prevalence since the COVID pandemic. If we take it on the curves, then if we look on the occupational health, it is very good to note, like we said, that we are now -5% in the connected employees, but it is now bottoming out or has bottomed out. Then the underlying impacts remain the same. We have the macroeconomic component where there is less employed. And then in dire times, employers are spending less into employee wellbeing. And then we have the actual part where we have the ongoing strong program to address this one, but at the same time, the connected employees and the large account sales cycles are longer. So we are getting back on growth in the second half of this year. Public sector has now been bottoming out. As we see, it is now a minuscule bar in the chart. And the consumer segment is showing positive momentum overall, supported by the Kela 65 and general market trends. If we then take a segue with that one to the portfolios, we now see that in the consumer part, the dental business has actually been the best performing in relative terms of our businesses. They are basically flat while other modalities have been clearly down. This is a positive, and hopefully also reflects the future demand environment. We have then to note that in the portfolio numbers we have the divestment of child welfare. It's visible in the bar order in here. Outsourcing is down 50%. We have known that the contracts are expiring and ending. Staffing is still having negative momentum in the Wellbeing Services County market. But also, that one is now little by little stabilizing, and dental, as said, is positive in relative terms in the performance. And we have announced the Hohde acquisition. That one is progressing well in a very good and positive dialogue with the authorities, and we are expecting the closing in the second half. And now, based on the current visibility, it looks like it will be rather third quarter than fourth quarter. But obviously, in these processes, there are variables that are beyond our control. But as said, solid positive dialogue with the authorities. And if I were to guess, it would be rather in Q3 for the closing than in Q4, then going to Sweden. We are having a weak market. It is a continued weak market, and Sweden, as an export-oriented nation, is also having their share of the market environment. At the same time, it's good to know that our efficiency is in place. We have the Adjusted EBIT margin. Our margin is now improving, with absolute numbers up 50%, give or take almost 60%. Obviously, within our scale, that is peanuts in the total absolute numbers, but it's signaling that we are moving in the right direction. If we then look beyond the efficiency. Our next battle here is the growth, and we already now see that our connected employees are increasing. But at the same time, the behavior of employers is similar to that in Finland, with their activity dampened by the weak macro. But we have the means and the tools for growth here, and we are confident that this will improve, as we have iterated many times earlier. When talking about investments. We continue our investment cycle. We are now at 56 million on the LTM, and I think that it's good to highlight from here that what we are doing is facing the real world. It is in production. It is in use. Our. Our brightest investment is Ella. It's the user interface for professionals. It's already live. We have been rolling it out to wider user groups with improved functionalities, and we are seeing continuous growth on the usage rate. So this is live. This is not something that happens at the back office and then one day comes out of nowhere. We are actively implementing this. The same applies to our joint venture, Medhelp. We have in March rolled out this to customers. We have paying customers on this one and we are continuing this one. So what we are doing is already now impacting us positively. If we then look at the balance sheet, we continue to have a positive balance sheet position. Our Net Debt to EBITDA is at 2.4. It has been increasing due to weak cash flow in Q1 and reduced profitability in Q1. But if we double-click that one, we are in a good position. And from a cash flow perspective, it is good to note that we are a negative net working capital company, which is obviously positive from a balance sheet perspective. But when revenues decline, our cash flow also weakens. It also weakens because we don't actually release net working capital; instead, we increase it, which impacts us negatively. Then the second component on the cash flow is that if you look at the taxes paid now in Q1, we paid taxes from the record profits of 2025. And that is having a negative impact on the cash flow. So all in all, our balance sheet is strong. We can continue to invest. We are not limited by the balance sheet. But at the same time, we are working on the cash flow. And the key component in there is going back on growth. Then before going to guidance, let's take a quick view on the market environment. First of all, if we look at the red arrows, they are all pointing down. This is weaker than we originally expected in February. We have had negative momentum through all peer groups. And then we have had incidents in the world that are also impacting, for example, the consumer confidence that we are showing now, referring especially to the Iranian war. So the market environment in Q1 has been exceptionally weak. However, if we then look at the next 12 months and look further, the arrows in the outlook are actually the same as we had in February. And based on the data we have, if we believe that the bottom has been seen, we do know that public sector, both in Portfolio Businesses and Healthcare Services, is on a lower level. If we then look at the consumer market, dental is already performing well. If we then look at the consumer market, the dental is already performing well. As stated in relative terms, it was the best-performing peer group and segment. And then, regarding Kela 65. We have recently heard the news on the widening of the scope of Kela 65 and widening the scope of the services within Kela 65, which are positive. Insurance market continues to be in a positive momentum. And then we have Sweden, which still has positive macro forecasts, slightly coming down compared to February's post-Iranian war outlook, but they are still positive. So if we look at the market momentum, we believe that the market will improve. Then at the same time, we do know that this is tilting towards second half and the latter part of that one. So if we think about the developments, Q2 will definitely be difficult. Q3 is always seasonally low, and then Q4 is the place where we would see the impacts. And with these factors, we reiterate our guidance. We expect full year 2026 Adjusted EBIT to be 135 to €165 million. The estimates are based on the gradually improving demand environment, as explained earlier, and normalization of the upper respiratory infections in the second half. And as stated, profitability in the first half is expected to be below the first half of 2025. Furthermore, it is good to note that our scenarios at the moment are pointing rather below than above the midpoint of our guidance. So all in all, we have a difficult first half, but we have a strong, robust and efficient motor and we are investing in the future. So we are confident that we are also delivering with those investments. With these words. Thank you. And let's go to Q&A.
Thank you. So we are ready now for your questions. Do we have any questions from the phone lines?
If you wish to ask a question, please dial star five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial star five again on your telephone keypad. The next question comes from Iris Thiemann from NB Carnegie. Please go ahead.
Hi. I have a couple of questions. So I'll ask them one by one. So firstly, what data indicates that the market has bottomed out. Can you explain that?
How do you use it?
Yes. So basically, it depends how you look at it from the market perspective; we obviously continuously follow up our different types of data points, including consumer behavior and visits at different intervals, such as daily and weekly. And at least our internal data is indicating that we have now bottomed out. Then, from the perspective of the connected employees, we have already mentioned in the call that it has now been stabilizing, and the pipeline is gradually indicating opportunities for us to capture going forward. But when it comes to the external market, we are especially referring to our own internal data.
And I think it's important to note that now we are talking about sequential improvement. So the market has, if one cuts corners a little bit, reset to a post-inflation new normal. And now from that base, it starts slowly but steadily to grow.
Okay. And why did you keep your full year guidance even if your scenarios are pointing below the midpoint.
Well, we have actually discussed this topic also earlier that when we are within the range and we see that both ends of the range represent plausible scenarios, then we do not change it. So that is how we have behaved earlier, and that is how we continue to behave.
Okay. And can you still go through the drivers that will contribute to reaching the midpoint of the full year guidance, which implies basically only a 4% EBIT decline?
So first of all, I reiterated that we are likely to be rather below the midpoint than above it. So then it is up to you to decide on that one. But basically, the drivers that are pushing or impacting our guidance. And obviously you need to put your own finger in the air, how you take them within your estimates. But we have the upper respiratory diseases, we have the consumer confidence, and a general corporate behavior that we are expecting to improve from the current rock bottom. And then we are also confident that the demand from occupational health clients has bottomed out, and that we are getting forward with those ones in the second half. So these are the key drivers. If we look at our market, and then of course, the public sector behavior is expected to have bottomed out at the moment.
And then, a question regarding Portfolio Businesses: the margin decreased significantly from Q4 and Q1 last year. Is this a one-off or a level that we should expect for the coming quarters?
All in all, Portfolio Businesses is also facing the negative demand environment, especially from the public sector. And then it is good to know that now the outsourcing contracts have also been contributing value. And a decline in those ones will no longer deliver margin expansion. But decline in revenues is negative for us in the total perspective. So we are expecting improved performance in the Portfolio Businesses also. Now, sequential improvement, as we explained, for the full year.
So question obviously is warranted. But if one looks at our plan and also our internal forecast. So, we are not expecting a drastic drop for upcoming quarters, as you mentioned regarding Q1. So we are realistically looking for a gradual improvement from a lower base.
Okay. But basically, is the margin decrease mainly related to the outsourcing business?
There is an impact. It is mainly related to the public sector, but basically the overall market environment has been weak. So that has been contributing throughout.
Okay. And my final question is related to the Finnish government's budget proposal that was just released. So is there anything negative or positive that you would like to highlight regarding private healthcare service providers.
If anything, clearly positive. So expansion of Kela 65 is a highly welcomed initiative. From our point of view, we have been investing in this segment. So, the user segment of seniors. We have been investing in Kela 65 and now expanding the scope of the service to more diagnostics and also allowing higher frequency of use will most probably increase the number of users and also frequency of use. That is welcome news.
Okay. That's all. Thank you.
As a reminder, if you wish to ask a question, please dial star five on your telephone keypad.
Hi, can you hear me? Hello.
We hear you.
We hear you. Fine. Can you hear us? Yes.
Go ahead.
Yes. Okay. Four questions. We'll take this one by one. You're calling first. The first quarter had to be down from last year. But how should we think about the second quarter relative to last year, given your comments regarding the market having bottomed out during the latter part of Q1?
The next question comes from Sami Sarkamies.
Thank you, Sammy. We identified.
Some.
Stickiness.
Some stickiness online.
But we don't guide per quarter. But it is clear that quarter two will be weak. But what we think about is sequential improvement in total. So, at the moment, it is not against comparables as weak as Q1 was.
Okay. And then, regarding connected employees, you're expecting this to start growing sequentially in the second half of the year. Have you already won these deals? And how are front book prices looking relative to your current back book prices?
Very good question. So deals are won and lost all the time. The real question when forecasting forward is the funnel: how many renewals you have and how many new opportunities you have. And then, against that, win rates are applied. And then of course you have the packages and scopes and price levels. So, what we are seeing now is a clear improvement in the new opportunities funnel. The new opportunities bucket is increasing all the time, and applying an average win rate to that. We see a clear increase from that source. On the other hand, renewals from our existing customer base are also a factor. That bucket is shrinking and renewal win rates are improving and really, really high. So, just mathematically looking forward, we can with confidence expect growth. It's not going to be a sort of a early on rapid and skyrocketing. But it starts to grow. And of course, we want to accelerate it over time. Then looking at the scopes, when these bids enter the tender space and comparing those with our current portfolio, the price levels are higher than existing ones. But then you need to of course do the full cycle of negotiations and go over the finish line. And only then do you see what the final package and the final price level are on those agreements. Finally bottomed out, and now looking forward and progressing more positively. Finally, it bottomed out, and is now looking forward and progressing more positively.
I may have missed, but did you give any commentary regarding cash flow in Q1? It was quite a bit below last year's level. So what are you expecting for the full year?
So basically what I iterated on the balance sheet slide was that first of all, cash flow was negatively impacted by the profitability. Then the second component is that we pay taxes from the previous record year. So all-time high profits lead to all-time high taxes, obviously. And then the third component is that our net working capital is structurally negative, which means that a decline in revenue negatively impacts our cash flow. And these are the three components. And obviously, taxes we don't pay twice. But the growth component is very important for us for the cash recovery when we are going forward.
Okay. And then my final question is on acquisition. Are you expecting to see any remedies from competition authorities? And what was your thinking on timing for closing when you announced the deal at the year end?
So I also iterated that one on the portfolio slide. First of all, we don't comment on the ongoing process from the content perspective. So that one, we don't state that here. But on the closing, we have stated that the closing is expected to happen on the second half. Based on the dialogue so far that we have had with the authorities, we believe that it's rather in Q3 than in Q4. So we have a positive, constructive dialogue continuously ongoing.
Yeah. And maybe still, even though you said we don't comment on that, I can say that, against the assumptions going in, what the process indicates and what is our current view on the sort of deal perimeter and the final package, I would say it's rational. It's rather slightly more positive than we thought going in.
Okay, thanks. I don't have any further questions.
There are no more questions at this time. So I hand the conference back to the speakers.
Thank you. We covered some of the questions from the webcast audience already earlier, but there are a few left. So starting with the cost structure and the adjustments made. What specific actions did we take and what actions are we still implementing going forward?
So we are, of course, adjusting as an agile company should for the lower demand and lower volumes, especially in our customer-facing activities in our operations. We have scaled down almost in line with the lower volume in our Healthcare Services operations, where the volumes were down by 11%. We were able to adjust FTEs by 10%. So that's a very good and robust achievement by ops. Ops team. Then one needs to note and remember that at the same time, we are also investing. So we are increasing resources in product, customer service sales, account management related activities, especially in occupational health care, but also in consumer and insurance related activities. But all in all, we have been able to adjust nicely. Looking forward, of course, given the negative cycle, we are using this window as an opportunity to also look at the overhead and some structures. We have a separate program related to applying AI in the back office functions. And that has started, but that's not really in the scope now when we are adjusting for the lower volume, but during the next 12 months, you will hear more about this project Nova.
Thanks. Then let's talk about the outsourcing in the portfolio businesses where we have seen the revenue decrease for quite some time. What does the remaining outsourcing portfolio look like? And do we expect further planned reductions beyond 2026?
Yes. So basically, if we look at the numbers for 2025, the outsourcing was delivering revenue of €55 million, give or take. And we have already, in our guidance, stated that we are expecting a roughly €20 million reduction in outsourcing portfolio revenues in 2026. And currently we are very clearly going towards that one.
And then beyond. 26, there's.
A. Beyond 2026, the remaining roughly €30 million portfolio will continue shrinking year on year. Yeah.
Exactly.
And there we are of course talking about outsourcing deals. And that's the focus for that sort of sliding curve. We are of course interested in partnerships with the healthcare counties and we are engaging actively right now; the sales funnel for larger new types of outsourcing deals is fairly thin, but engagement is active. And I would say, also according to our data and interviews, some 50% of the counties are interested in increasing their purchases from the private sector. But as we have seen, it's very difficult to put a date on when that starts to grow.
Yeah. And it should be noted that the remaining legacy contracts are on the higher end in the margin as well. So, getting healthier from that perspective as well. Then a question on the connected employees in the occupational health, we have seen a decrease for a few quarters for now. Can we just reiterate the reasons behind the decreases and what are the consequences of these decreases? For example, last year we had some negative media coverage, and did that have any impact?
It's a very, very good question. It's a combination of a couple of things. When we went into our profitability improvement program in late 23, one of the activities we were addressing back then was our very low price level in our main business, occupational health care. So the market had bypassed us in pricing for quite some time. And hence the gap was way too large to operate with adequate profitability in this business, so we implemented the increases in two steps. And in hindsight, I guess we could have done it a little bit more smoothly. So that maybe three steps would have been the better option. That latter price increase, coupled with the negative media coverage related to billing, was a negative trigger point for many companies and additional tendering. Since then, of course, it has been rectified and trust is back. We saw the damage last year, but as I said, the important thing is that after a negative developmental cycle, it has now bottomed out and the forward-looking funnel looks positive.
Exactly. Then, the last question is related to the cooperation with the insurance companies. We have talked about intensifying our cooperation and sort of next generation of insurance partnerships. And what's the plan there?
First of all, we are doing fine with insurance companies. So actually looking at the market view, even though the absolute volume in use of insurance coverage for healthcare spend, all in all, for all of the operators is negative at the moment. Our market share has been improving. So we are gaining in that market, even though it is currently in a negative cycle. So, what we are doing there. Of course, we are in a way putting ourselves in insurance company shoes and looking at what they are facing, what type of problems they are seeing, how they want our operations to serve the end customer, but also then what type of transparency we want and need to give them related to the effectiveness of care chains, their efficiency, and cost level. And we are building that sort of more active engagement all the time and getting positive feedback from that front. So with our excellent capabilities, we can be a better partner for insurance companies, guiding and steering customers and patients to the right modality of service and the right care chain, measuring the chain effectiveness, being very precise in billing, and also providing transparency on that and on the full scope of the population within those contracts. So there are many things that we are doing and continue to do to further improve our relationship.
Thanks. With that, we don't have any questions left. So, any closing words first from you? Juuso and Ville now.
Thank you. We will continue pushing for 2026.
Absolutely. It's a tough environment, but of course, we are. We are tougher. And now, looking forward, building on a lower base, but with a very positive view.
Thank you. And on a personal note, this is my last quarter with Terveystalo. It's been a pleasure working with you guys for the last almost nine years. I have full faith in this company and the team. And I believe that will come through as we navigate this cycle and from this industry transformation. Thanks. Have a great rest of the day and weekend.



















